The high prevalence of BRAF mutations in cancer has spurred interest in the development of specific BRAF inhibitors: Vemurafenib was the first BRAF inhibitor approved for the treatment of metastasized melanoma harboring BRAF V600E mutations in 2011 (Bollag et al., 2010; Chapman et al., 2011). This evidence concerns the gene BRAF and melanoma.